Haemonetics Corporation (HAE) Stock Forecast
HAE analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.27 / 5 from 11 analysts
- Price target
- $124.50 average of analyst targets
- Upside to target
- +5.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $1.30
- 52-week range
- $49.44 – $122.06
HAE analyst ratings
11 analystsNumber of analysts at each rating.
HAE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HAE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.29 | $1.21 | $1.37 | $1.27 | +1.7% | 11 |
| Next quarter (Dec '26) | $1.36 | $1.25 | $1.43 | $1.31 | +3.7% | 11 |
| Current fiscal year (FY2027) | $5.31 | $5.25 | $5.40 | $4.96 | +7.0% | 11 |
| Next fiscal year (FY2028) | $5.78 | $5.47 | $6.18 | $5.31 | +8.8% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HAE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $345.1M | $338.0M | $354.7M | +5.5% | 11 |
| Next quarter (Dec '26) | $357.6M | $351.2M | $366.6M | +5.5% | 11 |
| Current fiscal year (FY2027) | $1.42B | $1.40B | $1.45B | +6.2% | 11 |
| Next fiscal year (FY2028) | $1.50B | $1.46B | $1.58B | +5.5% | 11 |
HAE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HAE revenue: reported and forecast
HAE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.27 | $1.29 | $1.29 | $1.29 | $1.29 | +1.3% | 1 up · 0 down |
| Next quarter (Dec '26) | $1.39 | $1.35 | $1.35 | $1.36 | $1.36 | −2.0% | 2 up · 0 down |
| Current fiscal year (FY2027) | $5.22 | $5.30 | $5.30 | $5.31 | $5.31 | +1.8% | 2 up · 0 down |
| Next fiscal year (FY2028) | $5.63 | $5.74 | $5.74 | $5.78 | $5.78 | +2.7% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HAE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HAE beat in 12 of 12.
What analysts expect from HAE
11 analysts cover Haemonetics; their consensus rating is buy (4.27 on a 1–5 scale, where 5 is a strong buy). The average price target is $124.50, 5.3% above the latest close of $118.28. Analysts expect earnings of $5.31 per share for FY2027, +7.0% from a year earlier. For FY2028 the average estimate is $5.78 per share on revenue of $1.5 billion. Haemonetics beat the EPS estimate in 12 of the last 12 quarters.
Related: HAE income statement, HAE key metrics, HAE chart. See the HAE stock overview for the latest quote and news.
HAE forecast FAQ
What is Haemonetics's price target?
The average analyst price target for Haemonetics is $124.50, 5.3% above the latest close of $118.28.
Is Haemonetics a buy, hold or sell?
Of 11 analysts covering Haemonetics, 5 rate it a strong buy, 4 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Haemonetics's EPS forecast?
Analysts forecast $5.31 per share for FY2027 (range $5.25 to $5.40); for FY2028 the estimate is $5.78.
What is Haemonetics's revenue forecast?
The average revenue estimate for FY2027 is $1.4 billion, growth of 6.2%; for FY2028 it is $1.5 billion.
When does Haemonetics report earnings?
Haemonetics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $1.30.
Does Haemonetics usually beat earnings estimates?
Haemonetics reported EPS at or above the analyst estimate in 12 of the last 12 quarters.